



Date: 9 August 2019

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NOXOPHARM CORPORATE UPDATE INTERVIEW

Sydney, 9 August 2019: Noxopharm Limited (ASX: NOX) ('**Noxopharm**' or the '**Company**') today provides an FNN interview with Executive Chairman and Founder, Dr Graham Kelly, on the Company's third anniversary since ASX listing.

The interview will be found by visiting the Noxopharm website: www.noxopharm.com / Home Page / Recent Interviews or <http://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1595>

.....

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda[®] and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

About Veyonda[®]

Veyonda[®] (previously known as NOX66) is a suppository dosage formulation of the experimental anti-cancer drug, idronoxil, that leads in the body to the formation of a proprietary pro-drug form. Idronoxil specifically inhibits the ability of cancer cells to respond to stress, such as that induced by radiation, leading to loss of pro-survival signaling via sphingosine-1-phosphate. Idronoxil is also a STING agonist, activating the body's innate and adaptive immune systems.

www.noxopharm.com

Investor & Corporate Enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 9299 9690
E: David.Franks@atomicgroup.com.au

Media Contact:

Frank de Maria
Purposeful Communications
T: +1 347 647 0284
E: frank.demaria@purposefulcommunications.com

Forward Looking Statements



This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.